Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted <scp>EPOCH</scp>‐RLisa Giulino‐Roth, John P. Leonard, Carla Casulo et al.|British Journal of Haematology|2017Cited by 129
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R. Furman, Jeff P. Sharman, John C. Byrd et al.|Leukemia|2021Cited by 62
Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).Nathan Fowler, Beth Christian, Morton Coleman et al.|Journal of Clinical Oncology|2018Cited by 19
Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell LymphomaPeter Martin, Kristie A. Blum, Kami J. Maddocks et al.|Blood|2014Cited by 11
Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies: Pooled analysis from clinical trials.Richard R. Furman, Jeff P. Sharman, John C. Byrd et al.|Journal of Clinical Oncology|2020Cited by 11